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Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation affecting >5%
of the liver volume that is not explained by alcohol abuse. It is known that fructose gives rise to NAFLD
and it has been recently described that the ingestion of fructose in low amounts in aldolase B deficient
mice is associated with the development of fatty liver. Therefore, it is reasonable that patients with HFI
(Hereditary Fructose Intolerance) present fatty liver at diagnosis, but its prevalence in patients treated
and with adequate follow-up is not well documented in the literature. The aim of this study is to analyze
the association between HFI and NAFLD in treated patients.
Methods: A cross-sectional observational study was conducted. The population comprised 16 genetically
diagnosed HFI patients aged from 3 years to 48 and in dietary treatment of fructose, sorbitol and sacarose
exclusion at least for two years. Blood samples were obtained for analytical studies and anthropometric
measurements of each patient were performed.
Results: Patients presented a Body Mass Index (BMI) of 17.9 ± 2.9 kg/m2. The HOMA index and Quick
index were in normal range for our population. The S-adenosyl-methionine (SAM)/S-adenosyl-L-
homocysteine (SAH) ratio was increased in the patients in whom this analysis was performed. By im-
aging techniques it was observed that 9 of the 16 patients presented fatty liver (7 by hepatic MRI). Of
these 9 patients, only 3 presented hepatomegaly. 7 of 9 patients affected by the c.448G > C mutation had
fatty infiltration, of which three of them presented in addition hepatomegaly.
Conclusions: There is a high prevalence of fatty liver in HFI patients and it is not related to obesity and
insulin resistance. The diagnosis of fatty liver in HFI patients and, above all, the identification of new
therapeutic approaches, can positively impact the quality of life of these patients.
© 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.es University Hospital, Bio-
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The hereditary fructose intolerance (HFI; MIM 229600), caused
by the deficiency of the aldolase B enzyme (fructose-1,6-
bisphosphate aldolase) (EC 4.1.2.13) encoded by the ALDOB gene
(NM_000035.3), is an autosomal recessive hereditary metabolic
disease with a prevalence of 1:20000 [1]. Although HFI presents a
wide heterogeneity of phenotypic symptoms, the most prevalentism. All rights reserved.
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catalyzes different reactions including the reversible rupture of
fructose-1-phosphate in glyceraldehyde and dihydroxyacetone
phosphate and the excision of fructose-1,6-bisphosphate in two
trioses, dihydroxyacetone phosphate and glyceraldehyde-3-
phosphate. Therefore, this enzyme plays a very important role in
the control of the metabolism of fructose, as well as in the meta-
bolism of glucose, regulating both glycolysis and gluconeogenesis.
HFI's symptoms are usually initiated with the introduction of
complementary feeding in the infant, who reacts with a variety of
clinical signs such as failure to thrive accompanied by vomiting,
abdominal distension, jaundice and liver failure. HFI is also char-
acterized by a set of metabolism alterations that include hypogly-
cemia, metabolic acidosis, hypophosphatemia, hyperuricemia,
hypermagnesemia and hyperalaninemia [2] and elevated serum
carbohydrate deficient transferrin (CDT) [3]. The late diagnosis of
HFI associated with a continued intake of fructose leads to renal
and hepatic seizures, coma and even death. The early diagnosis of
HFI allows dietary treatment, consisting mainly in a diet free of
fructose, sucrose and sorbitol for life.
Non-alcoholic fatty liver disease (NAFLD) is characterized by fat
accumulation affecting >5% of the liver volume that is not
explained by alcohol abuse. It is the most common hepatic disorder
(with 25% of prevalence worldwide). This number varies widely by
geographic location and according to the methodology used for
diagnosis [4e7]. NAFLD is associated with a huge clinical and eco-
nomic burden [4]. This disease represents a wide spectrum of
conditions ranging from fatty liver, which consists of an accumu-
lation of fat in liver, mostly triglycerides, without inflammation or
cell damage, to non-alcoholic steatohepatitis, a form of steatosis
with inflammation and hepatocellular damage, which can progress
to cirrhosis and liver failure, as well as liver cancer [8]. During the
last decade, it has been observed that NAFLD is associated with an
increase in cardiovascular risk with acceleration of arteriosclerosis
and cardiovascular events [9].
It is known that fructose gives rise to NAFLD and it has recently
been described that the ingestion of fructose in low amounts in
aldolase B deficient mice is associated with the development of
fatty liver [10]. Therefore, it is reasonable that patients with HFI
present NAFLD at diagnosis, but its prevalence in patients treated
and with adequate follow-up is not well documented in the liter-
ature. The aim of this study is to analyze the association between
HFI and NAFLD in treated patients.
2. Subjects and methods
A cross-sectional observational study was conducted from
February 2016 to February 2017. The population comprised geneti-
cally 16 diagnosed HFI patients from 8 Spanish centres. 10 of the
patients were diagnosed in the infant period (0e2 years old), 3 of
them in the children period (2e14 years old) and the rest in the adult
period (>14 years old). We included HFI patients genetically diag-
nosed and in dietary treatment of fructose, sorbitol and sacarose
exclusion at least for two years. Exclusion criteria were: (1) poor
medical monitoring, (2) no therapeutic compliance (3), an associated
to NAFLD chronic disease or transplant and/or (4) medication related
to NAFLD. Patients signed the informed consent for the study.
Blood samples were collected in the morning after 8 h of fasting
for analytical studies and anthropometric measurements were
done.
2.1. Anthropometric variables
Recumbent length was measured with a measuring board and
weight with a manual baby scale until the age of 24 months.Please cite this article as: Aldamiz-Echevarría L et al., Non-alcoholic fatt
doi.org/10.1016/j.clnu.2019.02.019Thereafter, standing height was measured with a wall-mounted
stadiometer and body weight, to the nearest 100 g, with digital
scales. Patients were weighed barefoot and after overnight fasting.
The nutritional status was determined by calculating the body
mass index (BMI) as BMI¼weight (kg)/height2 (m2). Patients older
than 18 years old were classified as underweight (BMI < 18.5),
normal weight (BMI 18.5e24.99), overweight (BMI 25e29.99), and
obese (BMI  30) based on the WHO criteria. Subjects less than 18
years old were classified according to BMI by using The WHO Child
Growth Standards (Underweight: BMI percentile <15; Normal: BMI
percentile 15 to 85; Overweight: BMI percentile 85 to 95,
Obese: BMI percentile >95). Absolute and normalized values were
obtained through the use of the website: http://www.
webpediatrica.com/endocrinoped/antropometria.php. Sex, date of
birth and age at diagnosis were recorded.
2.2. Biochemical variables
Using standard laboratory methods, glycaemia, transaminases
(ALT, AST), Gamma GT, total bilirubin, albumin, lipid profile (total
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apoli-
poprotein A1 and B100) and insulin were analyzed.
HOMA index was calculated by the Matthews formula: insulin
(mU/mL)* [glucose (mmol/L)]/22.5]. HOMA index  a 2.5 indi-
cates insulin resistance. QUICK index: 1/log10 basal insulin (uUI/
mL)þ log10 basal glucose (mg/dL), which evaluates insulin sensitivity.
Study of sialotransferrins was done by HPLC technique (liquid
chromatography of high efficiency or high performance liquid
chromatography).
Study of methylation variables: SAM (S-adenosylmethionine),
SAH (S-adenosylhomocysteine) and SAM/SAH ratio. Blood samples
were collected from the antecubital vein into EDTA tubes, placed on
ice and immediately centrifuged at 1000g at 4 C for 5 min. Due to
the instability of SAM, it is very important to use an ice bath during
the process. The HPLC system consisted of an Agilent 1100 series
liquid chromatograph coupled to a UV absorbance detector of the
same series. SAM and SAH were separated on a Nucleosil C18 col-
umn (dimensions 12 cm 0.4 cm, particle size 5 mm) (Teknokroma,
Barcelona, Spain), that was kept at room temperature. The data
were recorded and treated using the Chem Station software.
2.3. Genetic studies
Sanger sequencing of the ALDOB gene was performed for each
patient at the Center of Diagnosis of Molecular Diseases (Madrid,
Spain).
2.4. Image analysis
Ultrasound and Hepatic Magnetic Resonance (MRI of 1.5 T) were
performed in the corresponding collaborative hospital.
2.5. Statistical analysis
Statistical analysis was performed using SPSS® 23.0 for Win-
dows (IBM, Chicago, IL). Data is reported as means (SDs) for normal
continuous variables, medians and IQRs for non-normally distrib-
uted. For qualitative variables and categorical data, the relative
frequency was calculated using contingency tables and chi-squared
test. Statistical significance was set at the p < 0.05 level.
2.6. Ethics
The study protocol was approved by the Research Ethics Com-
mittee of Basque Country. Written informed consent was obtainedy liver in hereditary fructose intolerance, Clinical Nutrition, https://
Fig. 1. Genetic mutations in the ALDOB gene found in our patients. 44% of the patients
in our study present the c.448G > C mutation.
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and patients included.
3. Results
3.1. Anthropometric characteristics
The study was conducted on a sample of 16 patients diagnosed
with fructosemia with confirmed genetic study: 5 males and 11
women aged from 3 years to 48. 81% of the patients were younger
than 18 years old. The age of diagnosis (0.1e45 years) varied
depending on the expression of the clinic, and based on the family
study for presenting affected siblings.
Table 1 shows the characteristics of the subjects involved in this
study. The subjects present a BMI lower than the Spanish average
for their age comparing each individual with the expected BMI
according to their age (median 17.4 in absolute values and 37.5 in
percentiles) [11]. None of them presents a situation of obesity and
only one of them has a BMI value at overweight levels.
3.2. Biochemical parameters
Table 2 shows the biochemical characteristics of the subjects.
The lipid and the liver profiles show values within normality. CDT is
within normal ranges.
3.3. Genetics
Genetic analyses of the patients revealed 4 different mutations
in the ALDOB gene (Fig. 1). With a total of 16 affected subjects, the
mutations c.448G > C (p.Ala150Pro) and c.360_363delCAAA in
homozygosis represent 44% and 37% respectively; c.448G > CTable 1
Current anthropometrics.
Absolute values Median Percentiles Median
Weight (Kg) 11e64.4 38.5 14e86 22.5
Height (cm) 86e166 150.25 11e82 46.5
BMI (kg/m2) 14.21e25.41 17.4 11e92 37.5
Table 2
Biochemical parameters.
Parameter n Median Range
Lipid profile
TOTAL CHOL mg/Dl [110e240] 14 191 149e315
HDL-CHOL mg/dL [>40] 14 77 37e124
LDL-CHOL mg/dL [<130] 14 120 49e179
TG mg/dL [30e170] 14 70 39e131
APO A1 mg/dL 9 202 165e219
APO B100 mg/dL 9 91 67e111
Hepatic profile
GOT/AST U/L [5e47] 16 26 18e358
GPT/ALT U/L [5e47] 16 25 15e438
GGT U/L [5e40] 16 14 10e204
FA U/L [30e106] 14 198 51e398
Albumin g/dL [3.5e5] 13 4.65 3.4e5.1
Total Bil mg/dL [0.2e1.2] 12 0.5 0.3e1
CDT
Disialotransferrins % [0,7e2,8] 12 1.6% 1e3.6
Trisialotransferrins % [1,7e8,7] 4 4.9% 4.35e9.2
Tetrasialotransferrin %s [60,0e84,6] 4 76.4% 68.6e77.9
Pentasialo þ hexasialotransferrins % [10,3e25,0] 4 15.3% 12.8e24.3
CHOL: cholesterol; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein;
TG: triglycerides; APO: apolipoprotein; GOT/AST: Glutamate-Oxaloacetate Trans-
aminase/Aspartate transaminase; GPT/ALT: Glutamate-Pyruvate Transaminase/
Alanine transaminase; GGT: Gamma-glutamyltransferase; FA: Fatty Acids; Bil:
bilirubin.
Please cite this article as: Aldamiz-Echevarría L et al., Non-alcoholic fatt
doi.org/10.1016/j.clnu.2019.02.019(p.Ala150Pro)/c.1005C > G (p.Asn335Lys) in heterozygosis, 13%;
c.448G > C (p.Ala150Pro) and c.360_363delCAAA, both in hetero-
zygosis, 6%.
3.4. Imaging analysis
Using imaging techniques it was determined that 9 of the 16
patients present fatty liver (7 by hepatic MRI). That means that in
56% of the subjects there was at least a slight and diffuse increase in
hepatic echogenicity, but periportal and diaphragmatic echoge-
nicity was still appreciable. This corresponds to grade 1 of hepatic
steatosis using established criteria [12]. Of these 9 patients, only 3
presented hepatomegaly, and none of them splenomegaly
(Table 3). Statistical analysis indicates that hepatomegaly is not
related to having hepatic steatosis in our patients (chi-square test
2.87, p > 0.05).
3.5. Genetic and hepatic alteration
Table 4 shows the correlation between liver lesions and the
most prevalent mutations, where seven of the nine patients
affected by the c.448G > C (p.Ala150Pro) mutation (78%) had
NAFLD, of which three of them presented hepatomegaly in addi-
tion. Regarding the c.360_363delCAAA mutation, only two of the
seven patients had NAFLD, and none of them had hepatomegaly.
Statistical analyses revealed an association between having
NAFLD and the genotype of the patient (chi-square test 3.87,
p < 0.05).
3.6. Methylation and insulin resistance study
Due to the difficulties of determining the levels of SAM, SAH and
SAM/SAH ratio, they were measured only in three local patientsTable 3
Nonalcoholic fatty liver.
Total Percentage % % <18 years % >18 years
Hepatic steatosis 9/16 56 77.78 22.22
Hepatomegaly 3/16 19 66.6 33.4
Chi-square test 2.87, p > 0.05.
Table 4
Correlation between liver lesions and the most prevalent mutations.
Mutation Absolute
values
NAFLD
(Yes/No)
Hepatomegaly
(Yes/No)
c.448G > C (p.Ala150Pro) 9 7/2 3/6
c.360_363delCAAA 7 2/5 0
Chi-square test 3.87, p < 0.05.
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Table 5
Levels of SAM, SAH and SAM/SAH ratio for three patients and reference range.
CASE 1 CASE 2 CASE 3 Range (uM)
SAM (uM) 4.07 11.7 3.6 2.0e3.5
SAH (uM) 0.09 0.05 0.05 0.05e0.24
SAM/SAH 42.4 247.4 72.4 11.8e30.3
L. Aldamiz-Echevarría et al. / Clinical Nutrition xxx (xxxx) xxx4with hepatic steatosis (Table 5) because the shipment of the rest of
the samples to analyze SAM and SAH provoked deterioration of the
metabolites. SAM and SAH are very unstable so it is very important
to use an ice bath during the sample preparation. Blood samples
must be collected and placed on ice immediately and centrifuged.
SAM concentrations and SAM/SAH ratio were above reference
values indicating the altered methylation cycle [13]. In these pa-
tients the HOMA index (0.43e1.34) and Quick index (0.37e0.45)
were in normal range for our population [14].4. Discussion
Our data confirm the high prevalence of the c.448G > C
(p.Ala150Pro) pathogenic variant in our patients (44%) as previ-
ously reported in other large European and USA cohorts [15,16]. The
mutation is a G/C change in exon 5 that creates a new recognition
site for the restriction enzyme Ahall and results in an amino acid
substitution (Ala/Pro) at position 150 of the protein within a
critical region for substrate binding. This could explain that almost
78% of our patients with the c.448G > C (p.Ala150Pro) variant
presented the fatty infiltration, unlike the other mutations, which,
despite representing almost 40% of the sample, were not associated
with NAFLD. In addition, hepatomegaly has been found in three
patients with this mutation.
NAFLD is traditionally associated with patients with hereditary
intolerance to fructose with poor metabolic control and a high BMI,
however, in our analysis all patients who have been studied have
followed adequate metabolic control and their BMI is within
normal range. This allows us to establish a strong relationship be-
tween NAFLD and the treated fructosemia, since more than half of
the patients had this hepatic alteration.
Ultrasonography is the most inexpensive and widely available
imaging test for NAFLD. Typical sonographic findings of NAFLD are
hepatomegaly and increased echogenicity. Unfortunately, ultraso-
nography is not sensitive if less than 30% of the liver is involved by
steatosis. Variability in operator skill and the limiting body habitus
of the typical NAFLD patient can lead to inadequate or inconsistent
results. Although changes of cirrhosis and portal hypertension may
be identified on ultrasound, it is neither a sensitive nor specific
modality for this diagnosis. Given these limitations, other imaging
studies are being investigated for the diagnosis and risk stratifica-
tion of NAFLD patients. Magnetic resonance imaging, including
magnetic resonance spectroscopy, has shown good sensitivity and
specificity in detecting and quantifying steatosis [17]. In our study,
the vast majority of the NAFLD diagnosis was done by hepatic MRI,
but its percentage can be under-diagnosed because many of the
patients only had the ultrasonography as image test.
Currently there are no data on the physiopathological mecha-
nisms that produce fatty liver in patients with HFI. Previous studies
have established a clear relationship between the accumulation of
fat in the liver and the inhibition of the protein kinase activated by
AMP (AMPK), both in animal models of obesity [18] and in human
metabolic diseases such as the insulin resistance, obesity and
sedentary life [19]. AMPK is a protein regulated by posttranslational
modifications like phosphorylation and also allosterically regulated
through the competitive union of ATP, so that the AMPK oftenPlease cite this article as: Aldamiz-Echevarría L et al., Non-alcoholic fatt
doi.org/10.1016/j.clnu.2019.02.019functions as a sensor of the ratio between AMP/ATP and/or ADP/
ATP, which reflect cellular energy levels. Thus, it has been described
that the activation of AMPK leads to the inhibition of energy-
consuming anabolic pathways, such as the synthesis of fatty acids
and sterols, and the activation of catabolic pathways that produce
energy, such as the b-oxidation of fatty acids [20].
On the other hand, the accumulation of fructose-1-phosphate in
HFI patients with aldolase B deficit carries a depletion of free
inorganic phosphate [21]. This decrease in the reserve of cellular
inorganic phosphate activates the enzyme AMP deaminase [22]. It
has been documented in HFI patients, using magnetic resonance
spectroscopy, that the accumulation of hepatic fructose-1-
phosphate and the decrease in hepatic ATP concentration be-
tween 40 and 60% after infusion of 200 mg/kg of fructose, is so
small that it did not even increase the concentration of uric acid
above the values of normality [23,24]. In addition, it has been found
that some drugs that activate AMPK act through inhibition of the
AMP deaminase [25]. These evidences suggest that in HFI patients,
the accumulation of fructose-1-phosphate and the decrease in
associated free inorganic phosphate may inhibit the activation of
AMPK, through the activation of the deaminase AMP, leading to a
decrease in the b-oxidation of fatty acids, resulting in the accu-
mulation of fatty acids in the form of triglycerides in the liver.
Lipidomic studies have revealed that NAFLD is characterized by
an increase in lipogenesis, and the activity of desaturases and lip-
oxygenase [26]. Other metabolic disturbances described in NAFLD
are changes in the proportion of phosphatidylcholine and phos-
phatidylethanolamine [27,28].
In recent years, a restriction of dietary methionine intake to
approximately 2 mg/kg BW/d has been associated with an increase
in hepatic b-oxidation in obese adults with metabolic syndrome
[29]. The same association was observed in animal models of
obesity with a 0.12% methionine restriction diet [30]. Methionine is
an essential amino acid, component of the methylation cycle, a
major regulator of detoxification, inflammation, energy production,
and DNA maintenance processes among others. It has also been
observed that changes in the methylation index, quantified by the
ratio of the intermediaries S-adenosyl-methionine (SAM) and S-
adenosyl-L-homocysteine (SAH), are directly associated with a
deregulation of the export of hepatic lipids mediated by very low
density lipoproteins (VLDL), which are responsible for transporting
triglycerides, cholesterol esters and phospholipids from the liver to
the extrahepatic tissues [31]. The increase in methionine in blood is
considered a warning symptom for the diagnosis of HFI [32].
Although in our work a small number of HFI patients with fatty
liver have been studied, we have observed an increase in the ratio
SAM/SAH that is associated with changes in the methylation cycle.
Recent studies have described the beneficial effects of a methionine
limited diet, with a very important role in regulating the methyl-
ation cycle, so that this diet increases hepatic b-oxidation, resulting
in a decrease in the levels of phosphatidylethanolamine in the
VLDL-TG long molecules enriched in apolipoprotein E.
It should be considered that a limited diet in methionine could
be beneficial for the prevention and/or treatment of fatty liver in
HFI patients, acting at two levels, increasing the beta-oxidation of
fatty acids and optimizing the lipids transport to extrahepatic tis-
sues. We must have in mind that the dietary treatment of these
patients favors a high protein diet.
It is important to emphasize that fatty liver often evolves to
steatohepatitis, hepatic fibrosis, cirrhosis and hepatic failure, and is
associatedwith an increased risk of cardiovascular disease, diseases
associated to a great morbidity and mortality. Therefore, the diag-
nosis of fatty liver in HFI patients and, above all, the identification of
new therapeutic approaches, can positively impact the quality of
life of these patients.y liver in hereditary fructose intolerance, Clinical Nutrition, https://
L. Aldamiz-Echevarría et al. / Clinical Nutrition xxx (xxxx) xxx 5This study has some limits that reduce the power of the results:
first it is a retrospective study that looks at patients at different ages
and stages of disease; therefore we cannot be entirely certain of the
clinical course of NAFLD. Second, the limited sample size precludes
proper statistical analysis and a prospective and larger study is
necessary to better clarify the evolution of the disease. Neverthe-
less, we believe that our study enriches the knowledge of the
pathologic liver changes in hereditary fructose intolerance disease.
Obviously, more functional data and a longer follow-up are
necessary to better understand the pathophysiological mechanism
of NAFLD in this genetic disorder in order to develop novel thera-
peutic approaches.
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